Skip to main content

GSK plc

GLAXF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001131399

No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.

Other share classesGSK

Currency
GBP
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 12:30 PM ET

Amounts are in GBP, the currency GSK plc reports in. Lines marked ≈ US$ convert key figures to US dollars.

Income statement

Each column is one fiscal year, newest first.

Income statement of GSK plc, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
RevenueGBP 32.7B≈ US$43.1BGBP 31.4B≈ US$40.1BGBP 30.3B≈ US$37.7BGBP 29.3B≈ US$36.3BGBP 34.1B≈ US$47.0B
Cost of revenueGBP 9.02BGBP 9.05BGBP 8.56BGBP 9.55BGBP 11.6B
Gross profitGBP 23.6BGBP 22.3BGBP 21.8BGBP 19.8BGBP 22.5B
Research and developmentGBP 7.53BGBP 6.40BGBP 6.22BGBP 5.49BGBP 5.28B
Selling, general and administrativeGBP 9.09BGBP 11.0BGBP 9.38BGBP 8.37BGBP 11.0B
Operating incomeGBP 7.93BGBP 4.02BGBP 6.75BGBP 6.43BGBP 6.20B
Interest expenseGBP 701.0MGBP 669.0MGBP 792.0MGBP 879.0MGBP 784.0M
Income taxGBP 1.11BGBP 526.0MGBP 756.0MGBP 707.0MGBP 346.0M
Net incomeGBP 6.29B≈ US$8.30BGBP 2.95B≈ US$3.77BGBP 5.31B≈ US$6.60BGBP 15.6B≈ US$19.3BGBP 5.10B≈ US$7.01B
EPS, basicGBP 1.41GBP 0.632GBP 1.22GBP 3.71GBP 0.876
EPS, dilutedGBP 1.39GBP 0.622GBP 1.20GBP 3.66GBP 0.866
Weighted shares, basic4.05B4.08B4.05B4.03B5.00B
Weighted shares, diluted4.12B4.14B4.11B4.08B5.07B
Margins and growth
Gross margin72.4%71.2%71.8%67.4%66.0%
Operating margin24.3%12.8%22.2%21.9%18.2%
Net margin19.3%9.4%17.5%53.3%14.9%
Revenue growth, year over year+4.1%+3.5%+3.4%−14.0%0.0%
Net income growth, year over year+113.1%−44.4%−66.0%+206.5%−20.2%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of GSK plc, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Cash and equivalentsGBP 3.40BGBP 3.87BGBP 2.94BGBP 3.72BGBP 4.27B
Accounts receivableGBP 7.47BGBP 6.84BGBP 7.38BGBP 7.05BGBP 7.86B
InventoryGBP 5.92BGBP 5.67BGBP 5.50BGBP 5.15BGBP 5.78B
Total current assetsGBP 17.5BGBP 17.0BGBP 18.6BGBP 20.8BGBP 18.7B
Property, plant and equipmentGBP 9.32BGBP 9.23BGBP 9.02BGBP 8.93BGBP 9.93B
GoodwillGBP 7.02BGBP 6.98BGBP 6.81BGBP 7.05BGBP 10.6B
Intangible assetsGBP 16.7BGBP 15.5BGBP 14.8BGBP 14.3BGBP 30.1B
Total assetsGBP 61.1B≈ US$82.2BGBP 59.5B≈ US$74.5BGBP 59.0B≈ US$75.2BGBP 60.1B≈ US$72.6BGBP 79.1B≈ US$106.8B
Accounts payableGBP 15.4BGBP 15.3BGBP 15.8BGBP 16.3BGBP 17.6B
Short-term debtGBP 3.01BGBP 2.35BGBP 2.81BGBP 3.95BGBP 3.60B
Total current liabilitiesGBP 21.4BGBP 21.7BGBP 21.1BGBP 22.8BGBP 23.7B
Long-term debtGBP 14.7BGBP 14.6BGBP 15.2BGBP 17.0BGBP 20.6B
Total liabilitiesGBP 45.2BGBP 46.4BGBP 46.2BGBP 50.0BGBP 57.8B
Shareholders' equityGBP 16.0BGBP 13.1BGBP 12.8BGBP 10.1BGBP 21.3B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of GSK plc, annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing20-F20-F20-F20-F20-F
Reported–––––
Operating cash flowGBP 7.74B≈ US$10.2BGBP 6.55B≈ US$8.38BGBP 6.77B≈ US$8.42BGBP 7.40B≈ US$9.16BGBP 7.95B≈ US$10.9B
Capital expendituresGBP 1.35BGBP 1.40BGBP 1.31BGBP 1.14BGBP 1.17B
Free cash flowGBP 6.39B≈ US$8.43BGBP 5.16B≈ US$6.59BGBP 5.45B≈ US$6.78BGBP 6.26B≈ US$7.74BGBP 6.78B≈ US$9.33B
Depreciation and amortizationGBP 2.31BGBP 2.55BGBP 2.29BGBP 2.15BGBP 2.38B
Stock-based compensationGBP 374.0MGBP 344.0MGBP 307.0MGBP 346.0MGBP 367.0M
Share buybacksGBP 1.38B––––
Investing cash flowGBP -4.23BGBP -1.23BGBP -1.59BGBP -8.77BGBP -1.78B
Financing cash flowGBP -3.69BGBP -4.73BGBP -5.64BGBP 823.0MGBP -7.59B
Ratio
Stock-based compensation, % of revenue1.1%1.1%1.0%1.2%1.1%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for GSK plc by cover date
Cover dateShares outstandingChange in a yearFiling
Dec 31, 20254.32B0.0%SEC
Dec 31, 20244.31B+0.1%SEC
Dec 31, 20234.31B0.0%SEC
Dec 31, 20224.31B−20.0%SEC
Dec 31, 20215.39B0.0%SEC
Dec 31, 20205.39B0.0%SEC
Dec 31, 20195.38B+0.1%SEC
Dec 31, 20185.38B+0.1%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • ≈ US$ figures convert GBP at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.